A-01

NMO-IgG blocker A-01 is a idiotype-specific blocker of neuromyelitis opticaimmunoglobulin g (nmo-igg) binding to aquaporin-4 (aqp4)

Smurf1-IN-A01 (A01) is a ubiquitin ligase Smad ubiquitination regulatory factor-1 inhibitor (Kd: 3.664 nM) that enhances BMP-2 responsiveness by preventing Smurf1-mediated Smad1/5 degradation.

CaCCinh-A01 is an inhibitor of the calcium-activated chloride channel (CaCC, 10 μM) and TMEM16A (IC50: 2.1 μM).

T16Ainh-A01 is a potent inhibitor of TMEM16A Chloride channel, inhibiting TMEM16A-mediated chloride currents (IC50 of 1 µM),and functions as a calcium-activated chloride channel (CaCC).

MDG486 belongs to androgen receptor ligand compounds with an IC50 greater than 100 µM, and can be used as a research tool in the field of adolescent development-related studies.

GA-017 is a potent, selective inhibitor of LATS1 and LATS2 (large tumor suppressor kinase 1/2), exhibiting IC50 values of 4.10 and 3.92 nM, respectively. This compound simultaneously acts as an activator of cell proliferation by promoting YAP/TAZ activation and their nuclear translocation. Additionally, GA-017 enhances cell growth in 3D culture conditions and augments the ex vivo formation of mouse intestinal organoids [1].

OXA-01 is a potent mTORC1 (IC50: 29 nM) and mTORC2 (IC50: 7 nM) inhibitor, demonstrating broad anti-tumor activity [1].

3HOI-BA-01 is a mammalian targeting effective rapamycin activation inhibitor.

TA-01 is a potent inhibitor of CK1 and p38 MAPK, with IC50 values of 6.4 nM for CK1ε, 6.8 nM for CK1δ, and 6.7 nM for p38 MAPK.

WU-FA-01, a hydrogenated derivative of WU-FA-00, is an antibacterial agent with robust activity against Gram-positive strains and possesses anti-inflammatory properties [1].

NRA-0160 is a selective antagonist of dopamine D4 receptor(Ki of 0.48 nM)

DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.

NA-014 (40) is a selective positive modulator of EAAT2 with an EC50 value of 3 nM.

TYA-018 is an orally available and selective HDAC6 inhibitor with cardioprotective properties for the study of dilated heart disease and heart failure.TYA-018 prevents sarcomere damage and decreases Nppb expression.

3-Deazaadenosine hydrochloride is an inhibitor of S-adenosylhomocysteine hydrolase (Ki: 3.9 µM). It has anti-inflammatory, anti-proliferative, and anti-HIV activity.

3-Deazaadenosine (3-DAA) is a potent S-adenosylhomocysteine (SAH) hydrolase inhibitor. It inhibits methylation reactions by inducing intracellular SAH accumulation, exhibiting antiviral, anti-inflammatory, and immunomodulatory activities.

AR-A014418 (GSK 3β inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor.

VA012 (compound 11) acts as a positive allosteric modulator (PAM) of the serotonin 5-HT2C receptor. It has been shown to reduce food intake and prevent weight gain during subchronic administration without causing central nervous system-related discomfort. VA012 is applicable in obesity research.

SGC-NSP2hel-1 (RA-0188293) is a potent and selective oral inhibitor of the nsP2 helicase, with a CC50 greater than 250 µM and a selectivity index over 4000. It exhibits broad-spectrum activity against various alphaviruses. In preclinical small animal models of chikungunya virus (CHIKV) disease, SGC-NSP2hel-1 reduces viral replication and limits virus-induced pathology by forming a stable complex with nsP2 and ATP.

Surgumycin is a carbonyl-conjugated pentaenic antibiotic.

Retifanlimab (MGA-012) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Retifanlimab is used in studies of Merkel cell carcinoma.

A011, a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor, exhibits an IC50 of 1.0 nM and triggers apoptosis as well as G2/M phase cell cycle arrest when combined with CPT-11, displaying notable antitumor activity [1].

Upanovimab (SCTA01) is a monoclonal antibody [1].

Lunsekimig (SAR443765) is an IL-13/TSLP bis-antibody that links a nano-antibody targeting IL-13 and a variable region of the heavy chain (VHH) targeting TSLP for use in asthma research.